IP Library Granted Patent US 10,611,814
Granted Patent B2
US 10,611,814 · App. 15/504,012 · Granted Apr 7, 2020

Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders

Inventors: Michael Bachmann (Kelkheim, DE); Armin Ehninger (Dresden, DE)
Assignee: GEMoaB Monoclonals GmbH
C07K14/7051C07K16/18A61K35/17C07K2317/34C07K2317/622C07K2319/02C07K2319/03C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,611,814
App. No.
15/504,012
Granted
Apr 7, 2020
Kind
B2
Abstract

The present invention relates to immune cell-based anti-cancer therapeutics and methods of using the therapeutics in the treatment of cancer.

Claims (17)

1. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1.

2. An isolated vector comprising the nucleic acid molecule of claim 1 .

3. The vector of claim 2 , wherein the vector is a viral vector selected from the group consisting of an adenoviral vector, an adenoviral-associated vector, a retroviral vector, a foamy viral vector, and a lentiviral vector.

4. An isolated cell comprising the vector of claim 2 .

5. The cell according to claim 4 , wherein the cell is a T cell, a Natural Killer cell, a cytotoxic T lymphocyte, or a regulatory T cell.

6. A polypeptide comprising the amino acid sequence encoded by the nucleic acid molecule of claim 1 , wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 27.

7. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 23.

8. An isolated vector comprising the nucleic acid molecule of claim 7 .

9. The vector of claim 8 , wherein the vector is a viral vector selected from the group consisting of an adenoviral vector, an adenoviral-associated vector, a retroviral vector, a foamy viral vector, and a lentiviral vector.

10. An isolated cell comprising the vector of claim 8 .

11. The cell according to claim 10 , wherein the cell is a T cell, a Natural Killer cell, a cytotoxic T lymphocyte, or a regulatory T cell.

12. A polypeptide comprising the amino acid sequence encoded by the nucleic acid molecule of claim 7 , wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 31.

13. A kit comprising a vector comprising the nucleotide sequence of SEQ ID NO: 1 and a polypeptide comprising the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 23, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 31.

14. An isolated nucleic acid molecule encoding a polypeptide comprising from amino-terminus to carboxy-terminus:

an antibody or antigen-binding fragment thereof comprising the amino acid sequences of SEQ ID NO:33 and SEQ ID NO:34;

(ii) a transmembrane domain encoded by the nucleotide sequence of SEQ ID NO:7; and

(iii) a signaling domain encoded by the nucleotide sequence of SEQ ID NO:8.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 18, 2024
From: BXLS V – DIAMANT L.P.
To: AVENCELL THERAPEUTICS, INC.
Reel/Frame 068941/0187 →
SECURITY INTEREST Recorded Jan 4, 2024
From: AVENCELL THERAPEUTICS, INC.
To: BXLS V - DIAMANT L.P., AS COLLATERAL AGENT
Reel/Frame 066026/0610 →
CHANGE OF NAME Recorded Mar 17, 2022
From: GEMOAB GMBH
To: AVENCELL EUROPE GMBH
Reel/Frame 059390/0606 →
CHANGE OF NAME Recorded Nov 23, 2021
From: GEMOAB MONOCLONALS GMBH
To: GEMOAB GMBH
Reel/Frame 058566/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2017
From: BACHMANN, MICHAEL; EHNINGER, ARMIN
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 043602/0138 →
Priority Claims (1)
EP 14182945 · Aug 29, 2014 · regional
Continuity (1)
Related Publication 20170240612A1 · Aug 24, 2017
Cited By (1)
US 12,195,555